1 / 69

Medicare s New Adventure: The Part D Drug Benefit

2. Funding Provided by the Kaiser Family Foundation, MedPAC, and DHHS/ASPEGeorgetown/NORC for Kaiser Family Foundation:

meg
Download Presentation

Medicare s New Adventure: The Part D Drug Benefit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. 1 Medicare’s New Adventure: The Part D Drug Benefit Jack Hoadley, Ph.D. Research Professor Georgetown University Health Policy Institute Spring 2007 Pharmaceutical Policy Seminar Series, Cornell University April 27, 2007

    2. 2 Funding Provided by the Kaiser Family Foundation, MedPAC, and DHHS/ASPE Georgetown/NORC for Kaiser Family Foundation: “Benefit Design and Formularies of Medicare Drug Plans: A Comparison of 2006 and 2007 Offerings – A First Look,” November 2006 http://www.kff.org/medicare/upload/7589.pdf “An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans,” April 2006 http://www.kff.org/medicare/upload/7489.pdf NORC/Georgetown for MedPAC: Cited in MedPAC June 2006 Report to Congress, Chapters 7 and 8 “Part D Plan Offerings” http://www.medpac.gov/publications/congressional_reports/Jun06_Ch07.pdf “How Beneficiaries Learned About the Drug Benefit and Made Plan Choices” http://www.medpac.gov/publications/congressional_reports/Jun06_Ch08.pdf NORC/Georgetown for DHHS/ASPE: “Issues in the Design and Implementation of Drug Formularies and Therapeutic Classes,” September 2005 http://aspe.hhs.gov/health/reports/05/drugformularies/report.pdf

    3. 3 General Background

    4. 4 Evolution of Part D Original Medicare law did not cover outpatient drugs Competing plans by both parties President limited budget for MMA to $400B over 10 years MMA became law 12-8-2003 First open season: 11-15-2005 to 5-15-2006 Benefit started 1-1-2006

    5. 5 Key Characteristics of Medicare Part D First coverage for outpatient prescription drugs Reliance on competing private, stand-alone drug plans Plans offered on a regional basis Managed-care alternative through Medicare Advantage Benefit includes subsidies for low-income beneficiaries Benefit has coverage gap (“doughnut hole”)

    6. 6 Shape of the Standard Benefit, 2006 and 2007

    7. 7 Sources of Drug Coverage, Medicare Beneficiaries, Before and After the MMA

    8. 8 Low-Income Assistance under Part D

    9. 9 What Low-Income Assistance is Available? Subsidies for beneficiaries with limited income and resources Reduces or eliminates most out-of-pocket expenses Beneficiaries qualify as a result of participation in Medicaid or by application Automatic enrollment in plans with premiums below a benchmark

    10. 10 Eligibility for the Low-Income Subsidy, 2007 Maximum subsidy Full-benefit dual eligibles (Medicare and Medicaid) Qualifying individuals Income below 135% of poverty / $13,784 (individual) or $18,482 (couple) Resources below $7,620 (individual) or $12,190 (couple) Partial subsidy Qualifying individuals Income 135-150% of poverty / $15,315 (individual) or $20,535 (couple) Resources below $11,710 (individual) or $23,410 (couple) Note: Resources include $1,500 ($3,000/couple) allowance for funeral or burial expenses.

    11. 11 The Standard 2007 Benefit for Beneficiaries Qualifying for the Low-Income Subsidy

    12. 12 Eligibility and Participation in Low-Income Subsidy Program, 2007

    13. 13 Educating Beneficiaries on Part D: How Did They Make Their Decisions?

    14. 14 Did Beneficiaries Seek Help in Deciding Whether to Enroll?

    15. 15 Did Beneficiaries Use and Find Helpful the Tools Provided by the Medicare Program?

    16. 16 How Important Were Various Factors in Deciding Whether to Enroll?

    17. 17 What Was the Main Reason for Not Enrolling?

    18. 18 How Important Were Various Factors in Picking a Specific Plan?

    19. 19 “It’s like going to a Chinese restaurant with three pages of entrees. There are lots of choices, and the choices are different, running the gamut from A to Z, covering a little to a lot. It’s too many choices.” “It’s too confusing because there’s a lot of information out there. After you’ve made your decision, how can you know you’ve made the best one?” “There is useful information out there, but it’s not information that my father has access to. He can’t use the computer, and that’s why I had to help him.” “This is like a crapshoot, because you know the meds you’re taking today, but all of a sudden, the drugs can change tomorrow and will not be covered. This is almost a gamble.” Beneficiaries Comments on Their Decisions

    20. 20 Has Enrollees’ Experience with their Part D Plan been Positive or Negative?

    21. 21 Enrollment in Part D Plans, 2006-2007

    22. 22 Part D Enrollment Nationwide, 2007

    23. 23 Enrollment, among Stand-Alone PDPs Nationwide, 2006

    24. 24 Plan Features in 2006-2007: Comparing Offerings by Number of Plans and Number of Enrollees

    25. 25 Enrollment and Plans Offered by Type of Organization, 2006-2007

    26. 26 Range of Monthly Premiums for All Stand-Alone PDPs, 2006-2007

    27. 27 Changes in Monthly Premiums from 2006 to 2007

    28. 28 Type of Benefit Design – All Standalone PDPs, 2006-2007

    29. 29 Coverage in the Gap – All Standalone PDPs, 2006-2007

    30. 30 Plan Premiums, by Type of Coverage in the Gap, All Standalone PDPs, 2007

    31. 31 Rules and Classification Systems for Formularies

    32. 32 Why Do Formularies Matter? Factor in beneficiaries’ selection of a plan Restriction on beneficiaries’ access to drugs Limitation on what physicians can prescribe Plan management of utilization and costs Tool to encourage appropriate drug use Leverage for negotiating prices Factor in containing plan, beneficiary, and federal costs

    33. 33 Basic Rules Plans Must Follow Therapeutic classification system for formulary Nondiscrimination criterion for overall benefit Pharmacy & therapeutics (P&T) committee Actuarial equivalence for cost sharing Exceptions and appeals

    34. 34 Therapeutic Classification System USP model guidelines Level 1: Therapeutic categories Level 2: Pharmacologic classes Level 3: Formulary Key drug types Plans may substitute their own system 74% of formularies used USP system in 2006

    35. 35 USP Analgesics Category, 2006 and 2007 (solid line=category, dashed=class, dotted=key drug type)

    36. 36 USP Antidepressants Category, 2006 and 2007 (solid line=category, dashed=class, dotted=key drug type)

    37. 37 Nondiscrimination Criterion Statute: Disapprove if design and benefits are likely to substantially discourage enrollment by certain beneficiaries Rule: Adequate coverage of the types of drugs most commonly needed by enrollees, as recognized in national treatment guidelines Preamble: Offer complete treatment options for a variety of medical conditions

    38. 38 Standards for a Formulary, 2007 2 drugs for each of 133 category/classes 1 drug for each of 141 key drug types “Most or all” drugs in selected classes But not all combination drugs or special formulations (extended-release, weekly dosing) Drugs cited in national treatment guidelines, risk adjustment categories, or in commonly prescribed drug classes Option of “specialty” tier for high-cost drugs

    39. 39 Formulary Coverage by Part D Plans

    40. 40 Number of National and Near-National Plans Covering Sample Drugs, 2007

    41. 41 Number of Sample Drugs Covered by Top 10 Plans, 2006-2007

    42. 42 Number of Sample Generic and Brand-Name Drugs Covered by Top 10 Plans, 2006-2007

    43. 43

    44. 44 Coverage of Cholesterol Drugs, Top 10 Plans, 2007

    45. 45

    46. 46 Coverage of Anti-Depressants, Top 10 Plans, 2007

    47. 47 Tiering Structure by Part D Plans

    48. 48 What Tier Structures Are Part D Plans Using in 2006?

    49. 49 Formulary Tier Placement of Sample Drugs, by Drug Class, 2007

    50. 50 Formulary Tier Placement of 78 Sample Brand-Name Drugs, 2006-2007

    51. 51 Use of Specialty Tier for Sample Drugs, Top 10 Plans, 2006-2007

    52. 52 Utilization Management

    53. 53 Application of Utilization Management Tools, by Drug Class, 2007

    54. 54 Application of Utilization Management Tools, by Top 10 Plans, 2007

    55. 55 Cost of Obtaining Drugs in the Initial Coverage Period

    56. 56 Typical Cost-Sharing Levels for PDPs, 2006

    57. 57 Variation in Cost Sharing Arrangements, 2007, Top 10 Plans

    58. 58 Median Monthly Cost for Sample Drugs in the Initial Coverage Period, Top 10 Plans, 2006-2007

    59. 59 Monthly Cost in Initial Coverage Period of Popular Drugs, Top 10 Plans, 2007 (I)

    60. 60 Monthly Cost in Initial Coverage Period of Popular Drugs, Top 10 Plans, 2007 (II)

    61. 61 Coverage and Monthly Cost of Statins for Treating High Cholesterol, By Plan, 2007

    62. 62 Coverage and Monthly Cost of SSRIs for Treating Depression, By Plan, 2007

    63. 63 What Problems Are Emerging?

    64. 64

    65. 65

    66. 66 The Status of Medicare Part D in 2007 and Beyond

    67. 67 What Are We Seeing in 2007? Mostly the same organizations, plus some new ones, offering benefits Modest changes in plan designs Modest growth in on-formulary drugs Modest increases in premiums and in the cost of sample drugs Little enrollment growth Fewer than 10% of beneficiaries switched plans for 2007

    68. 68 What Do We Expect for 2008? Potential shakeout of participating organizations Reduced federal risk sharing How long will poor performers continue? Greater shifts in beneficiary enrollment? Some changes in formulary guidance New requirement for key drug types Will there be larger changes in plan designs and formularies? Will plans shift focus from enrollment to cost containment?

    69. 69

    70. 70 Will Policymakers Make Changes? Potential for policy changes is affected by political forces Presidential election year politics Competing budget and spending priorities Long-term Medicare solvency issues Also by legislative procedures Different perspectives in House and Senate Need for 60 votes in the Senate CBO scoring issues

More Related